摘要
慢性乙型肝炎病毒感染及相关肝病仍是我国重要的公共卫生问题。目前,核苷(酸)类似物是抗病毒治疗的一线用药,但其长期服用的安全性问题也引起了临床医师的广泛关注。近期亚太肝病学会(APASL)会议报道长期富马酸丙酚替诺福韦治疗中伴发的低密度脂蛋白胆固醇水平升高,谨慎评价这种抗病毒治疗过程中的血脂异常,探讨其对终末期肝病发生风险的影响并提出应对策略具有重要的临床意义。
Chronic hepatitis B virus infection and its related liver diseases are still important public health problems in China.At present,nucleos(t)ide analogs are the first-line antiviral drugs,but the safety of their long-term use has also aroused widespread concern of clinicians.Recently,the annual meeting of the Asian-Pacific Association for the Study of Liver(APASL)reported that long-term treatment of tenofovir alafenamide fumarate was associated with the elevated level of low density lipoprotein cholesterol(LDL-C).It is of great clinical significance to carefully evaluate the dyslipidemia in the course of antiviral therapy,to explore its influence on the risk of occurrence of end-stage liver disease and to put forward the coping strategies.
作者
高原
李桂馨
陈红松
鲁凤民
GAO Yuan;LI Gui-xin;CHEN Hong-song(The Fourth Department of Liver, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China)
出处
《中国临床新医学》
2021年第3期251-255,共5页
CHINESE JOURNAL OF NEW CLINICAL MEDICINE
基金
国家“艾滋病和病毒性肝炎等重大传染病防治”科技重大专项“十三五”计划项目(编号:2017ZX10302201)
国家自然科学基金资助项目(编号:81672013)。
关键词
乙型肝炎病毒
核苷(酸)类似物
肝细胞癌
血脂异常
低密度脂蛋白胆固醇
Hepatitis B virus(HBV)
Nucleos(t) ide analogs(NAs)
Hepatocellular carcinoma(HCC)
Dyslipidemia
Low density lipoprotein cholesterol(LDL-C)
